These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
83 related items for PubMed ID: 1616956
21. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Rouault JP, Falette N, Guéhenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R, Samarut J, Magaud JP, Ozturk M, Samarut C, Puisieux A. Nat Genet; 1996 Dec; 14(4):482-6. PubMed ID: 8944033 [Abstract] [Full Text] [Related]
22. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex. Nourani A, Doyon Y, Utley RT, Allard S, Lane WS, Côté J. Mol Cell Biol; 2001 Nov; 21(22):7629-40. PubMed ID: 11604499 [Abstract] [Full Text] [Related]
28. An unexpected role for p53 in augmenting SV40 large T antigen-mediated tumorigenesis. Herzig M, Novatchkova M, Christofori G. Biol Chem; 1999 Feb; 380(2):203-11. PubMed ID: 10195427 [Abstract] [Full Text] [Related]
30. Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein. Wesierska-Gadek J, Schmid G. Cell Mol Biol Lett; 2001 Feb; 6(2):117-40. PubMed ID: 11544635 [Abstract] [Full Text] [Related]
31. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells. Cao Y, Gao Q, Wazer DE, Band V. Cancer Res; 1997 Dec 15; 57(24):5584-9. PubMed ID: 9407971 [Abstract] [Full Text] [Related]
32. The p53 gene and its role in human brain tumors. Bögler O, Huang HJ, Kleihues P, Cavenee WK. Glia; 1995 Nov 15; 15(3):308-27. PubMed ID: 8586466 [Abstract] [Full Text] [Related]
33. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. Huang SM, Schönthal AH, Stallcup MR. Oncogene; 2001 Apr 19; 20(17):2134-43. PubMed ID: 11360197 [Abstract] [Full Text] [Related]
34. [P53 and cancers]. May P, May E. Pathol Biol (Paris); 1995 Mar 19; 43(3):165-73. PubMed ID: 7675543 [Abstract] [Full Text] [Related]
35. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Shaulsky G, Goldfinger N, Rotter V. Cancer Res; 1991 Oct 01; 51(19):5232-7. PubMed ID: 1717142 [Abstract] [Full Text] [Related]
36. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP. Sherman L, Itzhaki H, Jackman A, Chen JJ, Koval D, Schlegel R. Virology; 2002 Jan 20; 292(2):309-20. PubMed ID: 11878933 [Abstract] [Full Text] [Related]
37. Signaling to p53: breaking the posttranslational modification code. Appella E, Anderson CW. Pathol Biol (Paris); 2000 Apr 20; 48(3):227-45. PubMed ID: 10858956 [Abstract] [Full Text] [Related]
38. Functional implications of the growth-suppressor oncoprotein p53. Montenarh M. Int J Oncol; 1992 Jun 20; 1(1):37-45. PubMed ID: 21584507 [Abstract] [Full Text] [Related]
39. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Molchadsky A, Rivlin N, Brosh R, Rotter V, Sarig R. Carcinogenesis; 2010 Sep 20; 31(9):1501-8. PubMed ID: 20504879 [Abstract] [Full Text] [Related]
40. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Michalovitz D, Halevy O, Oren M. Cell; 1990 Aug 24; 62(4):671-80. PubMed ID: 2143698 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]